Back
ESC Professional Premium Access

Effect on cholesterol remnants and residual lipid risk with PCSK9 inhibitors: the LIPID-REAL Registry

Session: Lipids - Drug therapy 2
Topic: Drug therapy
Speaker: Doctor A. Cordero (Elche, ES)
Event: ESC Congress 2022

Congress Presentation

About the speaker

Doctor Alberto Cordero

IMED Elche Hospital, Elche (Spain)
4 presentations
0 follower

6 more presentations in this session

Simulation study on LDL cholesterol target attainment, ASCVD events, and treatment cost of bempedoic acid in a representative German cohort of high- and very-high-CV risk patients

Speaker: Doctor J. Katzmann (Leipzig, DE)

Access
Abstract
Slides
Thumbnail

Effect of SLCO1B1 genotypes on statin intolerance and response to statins

Speaker: Mrs L. Davis (Harefield, GB) Doctor T. Khan (Harefield, GB)

Access
Abstract
Slides
Thumbnail

Persistence to long-term PCSK9 inhibitors treatment and its effectiveness in familial hypercholesterolemia: data from the SAFEHEART study

Speaker: Doctor R. Alonso (SANTIAGO, CL)

Access
Abstract
Slides
Thumbnail

LDL-C goal achievement and lipid-lowering therapy in patients by atherosclerotic cardiovascular disease subtype: the SANTORINI study

Speaker: Professor K. Ray (London, GB)

Access
Abstract
Slides
Thumbnail

Trends in management of cardiovascular risk factors in young adults who go on to develop coronary artery disease

Speaker: Doctor D. Vikulova (Vancouver, CA)

Access
Abstract
Slides
Thumbnail

Access the full session

Lipids - Drug therapy 2

Speakers: Doctor A. Cordero, Doctor J. Katzmann, Mrs L. Davis, Doctor T. Khan, Doctor R. Alonso...
Access
Thumbnail

About the event

Image

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb